Harvest Fund Management Co. Ltd Grows Holdings in Amgen Inc. (NASDAQ:AMGN)

Harvest Fund Management Co. Ltd boosted its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 15.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 31,657 shares of the medical research company's stock after buying an additional 4,161 shares during the period. Harvest Fund Management Co. Ltd's holdings in Amgen were worth $8,199,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of AMGN. Centricity Wealth Management LLC purchased a new stake in shares of Amgen in the 4th quarter valued at approximately $25,000. Legacy Investment Solutions LLC acquired a new stake in Amgen in the 3rd quarter valued at approximately $29,000. Synergy Investment Management LLC purchased a new stake in Amgen in the fourth quarter valued at approximately $34,000. Atala Financial Inc acquired a new position in Amgen during the fourth quarter worth $34,000. Finally, Heck Capital Advisors LLC purchased a new position in shares of Amgen during the fourth quarter worth $36,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Insider Activity

In other news, EVP Murdo Gordon sold 8,771 shares of Amgen stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the completion of the transaction, the executive vice president now owns 44,186 shares of the company's stock, valued at $13,025,590.94. The trade was a 16.56 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock worth $20,644,335 in the last 90 days. 0.69% of the stock is currently owned by corporate insiders.

Remove Ads

Analyst Ratings Changes

Several equities analysts recently issued reports on AMGN shares. Royal Bank of Canada reissued an "outperform" rating and set a $324.00 target price on shares of Amgen in a research note on Friday, January 24th. Wells Fargo & Company reissued an "equal weight" rating on shares of Amgen in a research note on Wednesday, February 5th. Truist Financial cut their target price on shares of Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a research note on Wednesday, January 8th. Leerink Partners decreased their price target on shares of Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Finally, StockNews.com lowered Amgen from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $314.04.

Amgen Stock Performance

NASDAQ AMGN traded up $1.00 during trading hours on Friday, hitting $316.04. 9,994,350 shares of the stock were exchanged, compared to its average volume of 2,553,454. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The company has a market cap of $169.78 billion, a price-to-earnings ratio of 41.86, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The stock has a 50-day moving average of $297.24 and a 200 day moving average of $298.80.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, equities research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be paid a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.01%. Amgen's dividend payout ratio (DPR) is presently 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.